Growth Metrics

Silence Therapeutics (SLN) Cost of Revenue (2020 - 2025)

Silence Therapeutics' Cost of Revenue history spans 6 years, with the latest figure at $12000.0 for Q4 2025.

  • On a quarterly basis, Cost of Revenue fell 99.41% to $12000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $215000.0, a 98.18% decrease, with the full-year FY2025 number at $215000.0, down 98.18% from a year prior.
  • Cost of Revenue hit $12000.0 in Q4 2025 for Silence Therapeutics, down from $64000.0 in the prior quarter.
  • Over the last five years, Cost of Revenue for SLN hit a ceiling of $2550.9 billion in Q2 2021 and a floor of $2119.4 in Q1 2021.
  • Historically, Cost of Revenue has averaged $127.5 billion across 5 years, with a median of $2.8 million in 2022.
  • The widest YoY moves for Cost of Revenue: up 143934.84% in 2022, down 100.0% in 2022.
  • Tracing SLN's Cost of Revenue over 5 years: stood at $2.8 million in 2021, then soared by 64.44% to $4.5 million in 2022, then tumbled by 63.09% to $1.7 million in 2023, then grew by 21.99% to $2.0 million in 2024, then plummeted by 99.41% to $12000.0 in 2025.
  • Business Quant data shows Cost of Revenue for SLN at $12000.0 in Q4 2025, $64000.0 in Q3 2025, and $85000.0 in Q2 2025.